Acasă › Boala Crohn › Illinois
Studii clinice pentru Boala Crohn în Illinois
18 studii pentru Boala Crohn caută participanți în Illinois.
Orașe în Illinois
Text oficial al studiului (în engleză)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Chicago Medical Center ( Site 5066), Chicago
- Endeavor Health ( Site 5018), Evanston
- GI ALLIANCE - GURNEE ( Site 5003), Gurnee
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 2 oct. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Midwest Digestive Health & Nutrition /ID# 285250, Des Plaines
- Gi Alliance - Glenview /ID# 283932, Glenview
- Illinois Gastroenterology Group /ID# 283933, Gurnee
- și încă 1
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Yapp, Rockford M.D. (Private Practice), Downers Grove
- GI Alliance - Glenview, Glenview
- Gastroenterology and Internal Medicine Specialists, SC, Lake Barrington
- și încă 3
În curs de recrutareFaza 4
Vârste de la 18 la 80 · Toate sexele · Actualizat 30 sept. 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Chicago Medical Center /ID# 267400, Chicago
- OSF St. Francis Medical Center /ID# 266973, Peoria
- Springfield Clinic Main Campus /ID# 267434, Springfield
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 25 sept. 2026 · NCT06548542Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Rush University Medical Center, Chicago
În curs de recrutareFaza 3
Vârste de la 18 la 70 · Toate sexele · Actualizat 24 sept. 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Rush University Medical Center-Site Number: 8400015, Chicago
- Midwest Digestive Health and Nutrition-Site Number: 8400136, Des Plaines
- GI Alliance - Glenview-Site Number: 8400068, Glenview
- și încă 1
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 23 sept. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee-Site Number: 8400049, Gurnee
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 23 sept. 2026 · NCT07184944A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Rush University Medical Center, Chicago
În curs de recrutareFaza 2
Vârste de la 18 la 80 · Toate sexele · Actualizat 22 sept. 2026 · NCT07483073A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Rush University Medical Center, Chicago
În curs de recrutareFaza 2
Vârste de la 18 la 80 · Toate sexele · Actualizat 22 sept. 2026 · NCT07483099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Chicago Medicine, Chicago
În curs de recrutareFaza 4
Vârste de la 18 la 70 · Toate sexele · Actualizat 9 sept. 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Chicago Medicine, Chicago
În curs de recrutare
Vârste de 18 ani și peste · Toate sexele · Actualizat 7 aug. 2026 · NCT05230173Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- OSF St. Francis Medical Center /ID# 262192, Peoria
În curs de recrutareFaza 3
Vârste de la 2 la 17 · Toate sexele · Actualizat 24 iun. 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Advocate Children's Hospital Park Ridge, Park Ridge
În curs de recrutareFaza 3
Vârste de la 2 la 17 · Toate sexele · Actualizat 22 iun. 2026 · NCT06405087A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Advocate Children's Hospital - Park Ridge - PIN, Park Ridge
În curs de recrutareFaza 3
Vârste de 2 ani și peste · Toate sexele · Actualizat 7 mai 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Advocate Children's Hospital Park Ridge, Park Ridge
În curs de recrutareFaza 3
Vârste de la 2 la 17 · Toate sexele · Actualizat 5 mai 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Northwestern University, Evanston
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 27 apr. 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Glenview
- Mirador Therapeutics Selected Site, Gurnee
În curs de recrutareFaza 2
Vârste de la 18 la 80 · Toate sexele · Actualizat 12 mar. 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Northwestern, Chicago
- University of Chicago, Chicago
În curs de recrutareFaza 1/2
Vârste de la 18 la 65 · Toate sexele · Actualizat 10 dec. 2025 · NCT06721962Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.